on Thursday said production of one of its key drugs, Lanreotide injection, will be paused as its supply partner, Pharmathen International S.A., is currently engaged in remediation at its plant in Rodopi, Greece. Lanreotide is used to treat hormone-related issues along with cancer tumour treatments. “Re-supply of Lanreotide to the market is expected to resume in H1 (Apr-Sept) of the financial year 2026-27. Until manufacturing restarts, the product will remain in limited supply, subject to quality clearance,” Cipla said in an exchange filing.
has secured final approval from the US Food and Drug Administration for Eltrombopag Tablets in strengths of 12.5 mg, 25 mg, 50 mg and 75 mg. Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad, it added. The tablets are indicated for the treatment of thrombocytopenia (low platelet count) in specific blood disorders.
, an innovation-led global biopharmaceutical company, has announced the successful completion of a Qualified Institutions Placement (QIP), raising Rs 4,150 crore from eligible qualified institutional buyers at the issue price of Rs 368.35 per share. The QIP that opened between January 12 and 14 attracted strong investor interest from a broad mix of domestic and international participants. The proceeds from the ǪIP will be primarily utilised to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited, including repayment of debt availed in this regard.